<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203313477225</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203313477225</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Proteinuria in membranous lupus nephritis: the pathology is in the podocyte</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Desai</surname><given-names>N</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313477225">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Cimbaluk</surname><given-names>D</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313477225">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lewis</surname><given-names>EJ</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313477225">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Whittier</surname><given-names>WL</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313477225">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203313477225"/>
</contrib>
</contrib-group>
<aff id="aff1-0961203313477225"><label>1</label>Division of Nephrology, Department of Medicine, Rush University Medical Center, Chicago, USA.</aff>
<aff id="aff2-0961203313477225"><label>2</label>Department of Pathology, Rush University Medical Center, Chicago, USA.</aff>
<author-notes>
<corresp id="corresp1-0961203313477225">William L Whittier, 1426 W. Washington Blvd, Chicago, IL 60607, USA. Email: <email>william_whittier@rush.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>5</issue>
<fpage>461</fpage>
<lpage>468</lpage>
<history>
<date date-type="received"><day>26</day><month>7</month><year>2012</year></date>
<date date-type="accepted"><day>12</day><month>1</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2013. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec12-0961203313477225"><title>Background</title>
<p>Patients with membranous lupus glomerulonephritis (MLN) can present with a broad range of urine protein excretion. The glomerular lesion underlying this functional abnormality has been presumed to be immune complexes which aggregate in the subepithelial area. However, the amount of proteinuria often fails to correlate with the quantity of immune deposits demonstrable on fluorescent and electron microscopy. The purpose of this study is to determine the correlation of alterations of the morphologic components of the glomerular capillary wall with the amount of proteinuria in MLN.</p>
</sec>
<sec id="sec13-0961203313477225"><title>Design</title>
<p>We conducted a retrospective clinicopathologic study of patients with lupus nephritis (<italic>n</italic> = 236). In those with pure MLN and proteinuria (<italic>n</italic> = 20), the degree of immune aggregates in the capillary walls and mesangium was detailed using fluorescent and electron microscopy. The degree of foot process effacement (FPE) was detailed using electron microscopy.</p>
</sec>
<sec id="sec14-0961203313477225"><title>Result</title>
<p>Eleven patients had nephrotic range proteinuria (≥3 g proteinuria/g creatinine (g/g)) and nine demonstrated subnephrotic range proteinuria (&lt;3 g/g) (nephrotic, 8.3 ± 5.1 g/g <italic>vs</italic>. subnephrotic, 1.63 ± 0.83 g/g, <italic>p</italic> = 0.001). All patients demonstrated peripheral capillary wall granular deposits by immunofluorescence microscopy, and the degree of moderate (2 +) to severe (3 +) deposition was not different (nephrotic, 8/11, 73% <italic>vs</italic>. subnephrotic, 5/9, 55%, <italic>p</italic> = 0.64). By electron microscopy, FPE (88.6 ± 11% <italic>vs</italic>. 48.3 ± 36.1%, <italic>p</italic> = 0.002) and foot process width (1798 ± 736 nm <italic>vs</italic>. 1000 ± 333 nm, <italic>p</italic> = 0.008) was greater in the nephrotic group compared with subnephrotic. There were no other histopathologic differences between the groups.</p>
</sec>
<sec id="sec15-0961203313477225"><title>Conclusions</title>
<p>In patients with MLN, a distinguishing morphologic feature of those with nephrotic range proteinuria is diffuse visceral epithelial cell FPE. We conclude that nephrotic range proteinuria in patients with MLN may be a manifestation of concomitant glomerular visceral epithelial cell dysfunction.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Renal Lupus</kwd>
<kwd>Systemic Lupus Erythematosus</kwd>
<kwd>Nephritis</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>edited-state</meta-name>
<meta-value>corrected-proof</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="sec1-0961203313477225" sec-type="intro"><title>Introduction</title>
<p>Membranous lupus nephritis (MLN) is characterized by widespread subepithelial or intramembranous immune aggregates and diffusely thickened glomerular capillary loops. Segmental scars and mesangial proliferation with expansion is variably seen. The clinical presentation of pure MLN is heralded by proteinuria in virtually all patients while the presence of nephrotic range proteinuria, hematuria, hypocomplementemia and anti-dsDNA antibodies are variable. Renal insufficiency and hypertension are unusual features at presentation.<sup><xref ref-type="bibr" rid="bibr1-0961203313477225">1</xref></sup> The mechanism underlying the development of proteinuria in MLN is generally believed to be related to complement mediated podocyte injury secondary to subepithelial immune aggregate deposition.<sup><xref ref-type="bibr" rid="bibr2-0961203313477225">2</xref><xref ref-type="bibr" rid="bibr3-0961203313477225"/><xref ref-type="bibr" rid="bibr4-0961203313477225"/>–<xref ref-type="bibr" rid="bibr5-0961203313477225">5</xref></sup> Data derived from an animal model of membranous glomerulonephritis supports this mechanism as being responsible for the initial proteinuric event. However, there are no reports correlating the degree of immune aggregate deposition in the glomerular basement membrane (GBM) to the severity of long term proteinuria. Recently, worsening of proteinuria was demonstrated in patients with idiopathic membranous nephropathy despite diminution of GBM deposits on biopsy.<sup><xref ref-type="bibr" rid="bibr6-0961203313477225">6</xref></sup> The patients in the latter study demonstrated diffuse foot process effacement (Rovin BH, personal communication, 8 March 2012).</p>
<p>The purpose of this study was to evaluate morphologic features of patients with pure MLN to identify whether any of these parameters are associated with the amount of proteinuria.</p>
</sec>
<sec id="sec2-0961203313477225" sec-type="materials|methods"><title>Materials and methods</title>
<p>We conducted a retrospective, clinicopathologic analysis of 236 native kidney biopsies from patients with systemic lupus erythematosus (SLE) submitted to Rush University Medical Center from 1984 to 2010. The biopsy specimens were processed by standard techniques for light, immunofluorescence, and electron microscopy. Kidney biopsies from patients with a histologic diagnosis of lupus membranous glomerulonephritis with or without the presence of mesangial proliferation and focal segmental glomerulosclerosis were reviewed. Light microscopy samples and photographs of immunofluorescence and electron microscopy from these patients were re-evaluated by a nephropathologist with no knowledge of the clinical parameters or clinical outcome. Biopsies were excluded from the analysis if they demonstrated evidence of endocapillary proliferation, necrosis, crescents or global glomerulosclerosis by light microscopy, and if electron micrographs were unavailable. Clinical, laboratory, and serologic data at baseline were obtained from chart review. Patients were excluded if they did not fulfill criteria for the diagnosis of SLE as defined by the American College of Rheumatology.</p>
<p>Seventy-one biopsies met the preliminary histologic inclusion criteria and were evaluated further. Forty-seven biopsies were excluded due to the presence of active or resolving segmental endocapillary proliferation, segmental necrosis, crescents, or global glomerulosclerosis. Of the remaining twenty-four biopsies, two patients did not fulfill four of the eleven American College of Rheumatology criteria for the diagnosis of SLE and were thus excluded. An additional two patients were excluded due to unavailable electron micrographs. The remaining 20 patients constituted the study group.</p>
<sec id="sec3-0961203313477225"><title>Pathology</title>
<p>Pathologic material on the 20 study patients included histologic sections stained for hematoxylin and eosin, periodic acid-Schiff, Masson’s trichrome, and methenamine silver periodic acid-Schiff (Jones) stains and photographs documenting fluorescence and electron microscopy. Total glomeruli and the number of glomeruli showing segmental sclerosis were recorded for each biopsy specimen. Each biopsy was reviewed for the presence of mesangial matrix expansion and mesangial cellular proliferation. Mesangial proliferation was considered present if there were greater than four cells per mesangial area. The presence and location of glomerular immune deposits (mesangial or granular basement membrane) was recorded and quantified on immunofluorescence microscopy (0 = negative, 1 + = minimally positive, 2 + = moderately positive, 3 + = severely or maximally positive). The burden of electron-dense deposits within each GBM was recorded and quantified as none, small, or massive. The number of electron dense deposits per capillary loop was also recorded in each photomicrograph and averaged.</p>
<p>The extent of epithelial cell foot process effacement (0 to 100%) was estimated after examination of all of the electron photomicrographs of non-sclerotic glomeruli in each case. There were five photographs per case, including scanning, intermediate- and high-magnification photographs of the capillary walls and mesangium. The photographs contained complete and partial glomerular capillaries/biopsy. Examples of biopsies with and without foot process effacement and varying degrees of deposits are shown in <xref ref-type="fig" rid="fig1-0961203313477225">Figure 1</xref>.
<fig id="fig1-0961203313477225" position="float"><label>Figure 1</label><caption><p>Representative electron micrographs (EMs) from patients with membranous lupus nephritis. (a) EM from a patient with 8.6 g proteinuria/g creatinine (g/g) demonstrating diffuse foot process effacement (FPE) and small deposits. (b) EM from patient with 8 g/g proteinuria (diffuse FPE, large deposits). (c) EM from a patient with 1.9 g/g proteinuria (no FPE, small deposits). (d) EM from a patient with 1.1 g/g proteinuria (no FPE, large deposits).</p></caption><graphic xlink:href="10.1177_0961203313477225-fig1.tif"/>
</fig></p>
<p>The length of each glomerular capillary loop and basement membrane was traced and measured using Image J software (a public domain, web based program developed at the National Institutes of Health and released for public use in 1997). Visceral epithelial cell foot processes, defined as “any connected epithelial segment abutting the basement membrane, between two neighboring filtration pores or slits”,<sup><xref ref-type="bibr" rid="bibr7-0961203313477225">7</xref></sup> were counted by hand. The mean foot process width on each electron micrograph was then calculated as follows:
<disp-formula id="disp-formula1-0961203313477225"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math1-0961203313477225"><mml:mrow><mml:mtext>FPW</mml:mtext><mml:mo>=π</mml:mo><mml:mtext>x</mml:mtext><mml:mo>∑</mml:mo><mml:mtext>GBM length</mml:mtext></mml:mrow></mml:math><graphic alternate-form-of="disp-formula1-0961203313477225" xlink:href="10.1177_0961203313477225-eq1.tif"/></disp-formula>
<disp-formula id="disp-formula2-0961203313477225"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math2-0961203313477225"><mml:mrow><mml:mn>4</mml:mn><mml:mo>∑</mml:mo><mml:mtext>foot process</mml:mtext></mml:mrow></mml:math><graphic alternate-form-of="disp-formula2-0961203313477225" xlink:href="10.1177_0961203313477225-eq2.tif"/></disp-formula>
where GBM length is the total GBM length measured in each picture and foot process is the total number of foot processes counted in each picture. The correction factor of π/4 corrects for presumed random variation in the angle of section relative to the long axis of the podocyte.<sup><xref ref-type="bibr" rid="bibr8-0961203313477225">8</xref></sup> Mean width of the foot processes (FPW) was calculated and recorded for each patient.</p>
</sec>
<sec id="sec4-0961203313477225"><title>Clinical and laboratory studies</title>
<p>Baseline demographic, clinical and laboratory information was obtained for each patient at the time of kidney biopsy. Medical records were reviewed to obtain information regarding gender, race, age, blood pressure, duration of SLE, and medications at the time of biopsy. Laboratory data obtained from the time of biopsy included degree of urinary protein excretion (spot urine protein/creatinine ratio), degree of hematuria, serum creatinine, serum albumin, total cholesterol level, and serologic studies (anti-nuclear antibody (ANA) titer, anti-double stranded DNA (dsDNA) antibody titer, serum complement components C3 and C4).</p>
<p>The cases were then dichotomized, based on amount of proteinuria at the time of biopsy, into a nephrotic group (≥ 3 g protein/g creatinine (g/g)) and a non-nephrotic group (&lt;3 g/g). The duration of SLE was defined as the time from presentation with SLE to the time of kidney biopsy.</p>
</sec>
<sec id="sec5-0961203313477225"><title>Statistical analysis</title>
<p>Continuous variables were compared using the unpaired <italic>t</italic>-test and categorical variables were compared using the Fisher’s exact test. A <italic>p</italic>-value of &lt;0.05 was considered significant. Values are reported as mean ± standard deviation. Medians are reported as the value with 95% confidence interval (CI).</p>
</sec>
</sec>
<sec id="sec6-0961203313477225" sec-type="results"><title>Results</title>
<sec id="sec7-0961203313477225"><title>Clinical</title>
<p>The clinical characteristics at the time of biopsy in both patient groups are shown in <xref ref-type="table" rid="table1-0961203313477225">Table 1</xref>. Nephrotic range (≥ 3 g/g) proteinuria was observed in 11 patients and nine patients demonstrated non-nephrotic (&lt; 3 g/g) proteinuria. Proteinuria in the nephrotic group was greater (mean 8.3 ± 5.1, median 6.8 (95% CI: 4.9–11.7) g/g versus mean 1.63 ± 0.83, median 1.4 (95% CI: 0.9–2.3) g/g) than in the non-nephrotic group (<italic>p</italic> = 0.0011). Patients with nephrotic range proteinuria were significantly younger (31.9 ± 10.8 years <italic>vs</italic>. 44.2 ± 11.4 years, <italic>p</italic> = 0.024), had higher serum cholesterol, and were significantly more hypoalbuminemic (2.49 ± 0.74 g/dl <italic>vs.</italic> 3.54 ± 0.35 g/dl, <italic>p</italic> = 0.001). There was no significant difference in either systolic or diastolic blood pressure at the time of biopsy, nor was there any significant difference in serum creatinine, lupus serology, incidence of acute kidney injury, or presence of microscopic hematuria. Only one patient in the nephrotic group presented with an elevated serum creatinine of 1.5 mg/dl.
<table-wrap id="table1-0961203313477225" position="float"><label>Table 1</label><caption><p>Baseline clinical characteristics</p></caption>
<graphic alternate-form-of="table1-0961203313477225" xlink:href="10.1177_0961203313477225-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>Subnephrotic</th>
<th>Nephrotic</th>
<th><italic>p</italic>-value</th>
</tr></thead>
<tbody align="left">
<tr>
<td><italic>n</italic></td>
<td>9</td>
<td>11</td>
<td/>
</tr>
<tr>
<td>Female (<italic>n</italic>)</td>
<td>9</td>
<td>10</td>
<td>1.00</td>
</tr>
<tr>
<td>Age (years)</td>
<td>44.2 ± 11.4</td>
<td>31.9 ± 10.8</td>
<td>0.02</td>
</tr>
<tr>
<td> Median</td>
<td>45 (26–62)</td>
<td>30 (18–51)</td>
<td/>
</tr>
<tr>
<td>African American (<italic>n</italic>)</td>
<td>3</td>
<td>8</td>
<td>0.17</td>
</tr>
<tr>
<td>Caucasian (<italic>n</italic>)</td>
<td>3</td>
<td>2</td>
<td>0.61</td>
</tr>
<tr>
<td>Hispanic (<italic>n</italic>)</td>
<td>3</td>
<td>1</td>
<td>0.28</td>
</tr>
<tr>
<td>SLE duration (months)</td>
<td>106.67 ± 62.8</td>
<td>28.58 ± 26.2</td>
<td>0.001</td>
</tr>
<tr>
<td> Median</td>
<td>108 (24–180)</td>
<td>36 (0–60)</td>
<td/>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>133.8 ± 20.3</td>
<td>117.8 ± 17</td>
<td>0.07</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>75.9 ± 17.3</td>
<td>76.7 ± 15.8</td>
<td>0.91</td>
</tr>
<tr>
<td>Proteinuria (g/g Cr)</td>
<td>1.63 ± 0.83</td>
<td>8.31 ± 5.1</td>
<td>0.001</td>
</tr>
<tr>
<td> Median</td>
<td>1.4 (0.3–2.69)</td>
<td>6.8 (3.5–21.0)</td>
<td/>
</tr>
<tr>
<td>Hematuria (<italic>n</italic>)</td>
<td>5</td>
<td>8</td>
<td>0.64</td>
</tr>
<tr>
<td>Creatinine (mg/dl)</td>
<td>0.9 ± 0.2</td>
<td>1.1 ± 0.6</td>
<td>0.40</td>
</tr>
<tr>
<td> Median</td>
<td>0.9 (0.5–1.1)</td>
<td>0.9 (0.6–1.3)</td>
<td/>
</tr>
<tr>
<td>Albumin (g/dl)</td>
<td>3.54 ± 0.35</td>
<td>2.49 ± 0.74</td>
<td>0.001</td>
</tr>
<tr>
<td> Median</td>
<td>3.6 (2.8–4.0)</td>
<td>2.2 (1.6–3.7)</td>
<td/>
</tr>
<tr>
<td>Cholesterol (mg/dl)</td>
<td>264 ± 113</td>
<td>312 ± 116</td>
<td>0.38</td>
</tr>
<tr>
<td> Median</td>
<td>234 (170–522)</td>
<td>300 (163–585)</td>
</tr>
<tr>
<td>ANA &gt;1:40 (<italic>n</italic>)</td>
<td>7</td>
<td>8</td>
<td>1.00</td>
</tr>
<tr>
<td>Elevated dsDNA</td>
<td>5</td>
<td>5</td>
<td>1.00</td>
</tr>
<tr>
<td>C3 (mg/dl)</td>
<td>103 ± 34.3</td>
<td>106 ± 43</td>
<td>0.84</td>
</tr>
<tr>
<td> Median</td>
<td>107 (41–149)</td>
<td>110 (40–172)</td>
<td/>
</tr>
<tr>
<td>C3 &lt; 80 (<italic>n</italic>)</td>
<td>2</td>
<td>3</td>
<td>1.00</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203313477225"><p>SLE: systemic lupus erythematosus; BP: blood pressure; g: gram; mg: milligram; dl: deciliter; ANA: antinuclear antibody; dsDNA: double stranded DNA antibody</p></fn></table-wrap-foot>
</table-wrap></p>
<p>The mean time from diagnosis of SLE to presentation with MLN and nephrotic proteinuria was 28.6 ± 26.2 months compared with those patients with non-nephrotic proteinuria (106.7 ± 62.8 months, <italic>p</italic> = 0.001). Five nephrotic patients presented within one year of the onset of SLE compared with none in the non-nephrotic group.</p>
</sec>
<sec id="sec8-0961203313477225"><title>Pathology</title>
<p>Pathologic findings are shown in <xref ref-type="table" rid="table2-0961203313477225">Table 2</xref>. The histopathology of both groups by light microscopy was similar. There was no significant difference between the nephrotic and subnephrotic groups with regard to the number of glomeruli sampled (33.4 ± 10.4 <italic>vs</italic>. 26.8 ± 17.3, <italic>p</italic> = 0.31). The degree of mesangiopathy and focal segmental glomerulosclerosis was similar between the two groups. No biopsy had evidence of acute tubular necrosis or tubulointerstitial nephritis.
<table-wrap id="table2-0961203313477225" position="float"><label>Table 2</label><caption><p>Baseline histologic characteristics</p></caption>
<graphic alternate-form-of="table2-0961203313477225" xlink:href="10.1177_0961203313477225-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>Subnephrotic</th>
<th>Nephrotic</th>
<th><italic>p</italic>-value</th>
</tr></thead>
<tbody align="left">
<tr>
<td><italic>n</italic></td>
<td>9</td>
<td>11</td>
<td/>
</tr>
<tr>
<td>Total glomeruli per biopsy</td>
<td>26.8 ± 17.3</td>
<td>33.3 ± 10.4</td>
<td>0.31</td>
</tr>
<tr>
<td colspan="4">Light microscopy</td>
</tr>
<tr>
<td>Segmental scars (<italic>n</italic>)</td>
<td>3</td>
<td>4</td>
<td>1.00</td>
</tr>
<tr>
<td>Mesangiopathy</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Cellular proliferation (<italic>n</italic>)</td>
<td>4 (44%)</td>
<td>8 (73%)</td>
<td>0.31</td>
</tr>
<tr>
<td>Matrix expansion (<italic>n</italic>)</td>
<td>2 (22%)</td>
<td>3 (27%)</td>
<td>1.00</td>
</tr>
<tr>
<td colspan="4">Immunofluorescence microscopy</td>
</tr>
<tr>
<td colspan="4">Mesangial deposits (IgG)</td>
</tr>
<tr>
<td>None</td>
<td>3 (33%)</td>
<td>5 (45%)</td>
<td>0.66</td>
</tr>
<tr>
<td>Trace</td>
<td>2 (22%)</td>
<td>0</td>
<td>0.18</td>
</tr>
<tr>
<td>1+</td>
<td>1 (11%)</td>
<td>1 (9%)</td>
<td>1.00</td>
</tr>
<tr>
<td>2+</td>
<td>2 (22%)</td>
<td>1 (9%)</td>
<td>0.56</td>
</tr>
<tr>
<td>3+</td>
<td>1 (11%)</td>
<td>4 (36%)</td>
<td>0.31</td>
</tr>
<tr>
<td>Overall +</td>
<td>6 (66%)</td>
<td>6 (54%)</td>
<td>0.67</td>
</tr>
<tr>
<td colspan="4">Peripheral granular deposits (IgG)</td>
</tr>
<tr>
<td>None</td>
<td>0</td>
<td>0</td>
<td>1.00</td>
</tr>
<tr>
<td>Trace</td>
<td>2 (22%)</td>
<td>3 (27%)</td>
<td>0.61</td>
</tr>
<tr>
<td>1+</td>
<td>2 (22%)</td>
<td>0</td>
<td>0.18</td>
</tr>
<tr>
<td>2+</td>
<td>3 (33%)</td>
<td>0</td>
<td>0.07</td>
</tr>
<tr>
<td>3+</td>
<td>2 (22%)</td>
<td>8 (73%)</td>
<td>0.06</td>
</tr>
<tr>
<td>Overall +</td>
<td>9 (100%)</td>
<td>11 (100%)</td>
<td>1.00</td>
</tr>
<tr>
<td colspan="4">Electron microscopy</td>
</tr>
<tr>
<td colspan="4">Intramembranous deposits</td>
</tr>
<tr>
<td>None</td>
<td>1 (11%)</td>
<td>3 (27%)</td>
<td>0.59</td>
</tr>
<tr>
<td>Small</td>
<td>6 (67%)</td>
<td>6 (55%)</td>
<td>0.66</td>
</tr>
<tr>
<td>Massive</td>
<td>2 (22%)</td>
<td>2 (18%)</td>
<td>1.00</td>
</tr>
<tr>
<td>Deposits per capillary (mean)</td>
<td>4.33 ± 7.7</td>
<td>2.5 ± 3.6</td>
<td>0.49</td>
</tr>
<tr>
<td colspan="4">Foot process effacement</td>
</tr>
<tr>
<td>Mean (%)</td>
<td>48 ± 36.</td>
<td>88.6 ± 11</td>
<td>0.002</td>
</tr>
<tr>
<td>Median (%)</td>
<td>50.0 (0–95)</td>
<td>95 (75–100)</td>
<td/>
</tr>
<tr>
<td>Foot process width (nm)</td>
<td>1000 ± 333</td>
<td>1798 ± 736</td>
<td>0.007</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0961203313477225"><p>nm: nanometer; IgG: immunoglobulin G</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Immunofluorescence (IF) microscopy revealed no difference in the degree of both mesangial and peripheral capillary immunoglobulin deposition between the groups (<xref ref-type="table" rid="table2-0961203313477225">Table 2</xref>). The degree of IgG immune complex burden in the peripheral capillary walls of 2 + and 3 + was not different (nephrotic, 8/11, 73% <italic>vs.</italic> subnephrotic, 5/9, 55%, <italic>p</italic> = 0.64). The degree of C3 immune aggregate deposition was 0–1 + for all biopsies, and was not different between the nephrotic and subnephrotic groups (nephrotic, 1 + , 7/11, 64%, <italic>vs</italic>. subnephrotic, 1 + , 3/9, 33%, <italic>p</italic> = 0.36). No biopsy revealed IF microscopy for C3 of 2 + or 3 + intensity. Electron microscopic examination of the nephrotic and subnephrotic patients demonstrated no statistically significant difference in the amount of electron dense deposits per capillary (2.50 ± 3.6 <italic>vs</italic>. 4.33 ± 7.7, <italic>p</italic> = 0.49).</p>
<p>Electron microscopic data of the epithelial cell foot processes are detailed in <xref ref-type="fig" rid="fig1-0961203313477225">Figure 1</xref> and <xref ref-type="table" rid="table2-0961203313477225">Table 2</xref>. The degree of foot process effacement (FPE) was 88.6 ± 11% in the biopsies from nephrotic patients compared with 48.3 ± 13.1% in the biopsies from subnephrotic patients (<italic>p</italic> = 0.002). Diffuse effacement was seen in all biopsies from nephrotic patients (median FPE 95% (range 75–100%)) with seven of 11 biopsies demonstrating at least 95% effacement. In contrast, five of eight biopsies from the subnephrotic group had less than 50% effacement (median FPE 50% (range 0–95%)) (<xref ref-type="fig" rid="fig2-0961203313477225">Figure 2</xref>). Morphometric analysis to determine quantitative FPW revealed a FPW of 1798 ± 736 nm in the nephrotic patients compared with 1000 ± 333 nm in the subnephrotic patients (<italic>p</italic> = 0.008) (<xref ref-type="fig" rid="fig3-0961203313477225">Figure 3</xref>).
<fig id="fig2-0961203313477225" position="float"><label>Figure 2</label><caption><p>XY plot of foot process effacement versus proteinuria for all patients. Open squares are the subnephrotic patients, closed circles are the nephrotic patients. A broad range of foot process fusion is noted among the subnephrotic patients (0–95%, <italic>p</italic> = 0.26). g/g: gram protein/gram creatinine.</p></caption><graphic xlink:href="10.1177_0961203313477225-fig2.tif"/>
</fig>
<fig id="fig3-0961203313477225" position="float"><label>Figure 3</label><caption><p>Average foot process effacement in membranous lupus nephritis for subnephrotic and nephrotic patients. The mean foot process width in nephrotic patients was 1798 ± 736 nm <italic>vs</italic>. 1000 ± 333 <italic>nm</italic> in the patients with subnephrotic proteinuria.</p>
<p>*<italic>p</italic> = 0.008</p></caption><graphic xlink:href="10.1177_0961203313477225-fig3.tif"/>
</fig></p>
</sec>
</sec>
<sec id="sec9-0961203313477225" sec-type="discussion"><title>Discussion</title>
<p>We conclude that a distinguishing morphologic feature associated with the presence of nephrotic range proteinuria in patients with MLN is diffuse effacement of the podocyte foot processes. The amount of proteinuria was not associated with the quantity or degree of immune aggregate deposition.</p>
<p>Effacement or “fusion” of the podocyte foot processes has been a well-known phenomenon in all types of the nephrotic syndrome. In accord with our own observations, foot process fusion tends to be diffuse and homogenous in the nephrotic syndrome. However, as we also observed, non-nephrotic glomerular lesions can be associated with a large range of the degree of foot process fusion (Figures <xref ref-type="fig" rid="fig2-0961203313477225">2</xref> and <xref ref-type="fig" rid="fig3-0961203313477225">3</xref>). We believe that this latter observation implies that the amount of foot process fusion is most likely not the consequence of proteinuria in MLN but rather the result of a more specific response, which, in SLE, could be immune mediated.</p>
<p>In other glomerular diseases, such as minimal change disease and IgA nephropathy, proteinuria is not correlated with foot process fusion.<sup><xref ref-type="bibr" rid="bibr7-0961203313477225">7</xref></sup> Our findings therefore may be specific to SLE or to MLN.</p>
<p>A variety of mechanisms have been studied in order to determine the basis of the changes in the podocyte in lupus nephritis. Antibody mediated damage may be one method, as anti-dsDNA cross reacts with the podocyte cytoskeleton protein α-actinin in murine models and human sera of patients with SLE.<sup><xref ref-type="bibr" rid="bibr9-0961203313477225">9</xref></sup> Immune-mediated or direct cell mediated processes have also been implicated.<sup><xref ref-type="bibr" rid="bibr10-0961203313477225">10</xref></sup> The expression of nephrin and podocin, two proteins which contribute to the integrity of the podocyte slit pore diaphragm and the barrier to proteinuria, is reduced in mild and severe forms of lupus nephritis.<sup><xref ref-type="bibr" rid="bibr11-0961203313477225">11</xref></sup> In murine models, this reduced expression correlates with foot process fusion.<sup><xref ref-type="bibr" rid="bibr11-0961203313477225">11</xref></sup> In addition, treatment with glucocorticoids and cyclophosphamide increases the expression of podocin and nephrin, and prevents the development of podocyte effacement.<sup><xref ref-type="bibr" rid="bibr12-0961203313477225">12</xref></sup> Future studies could specifically test the expression of podocin and nephrin in MLN.</p>
<p>The pathogenesis of nephrotic range proteinuria in patients with MLN is not completely understood. A great deal of our understanding derives from studies of the passive Heymann model of membranous glomerulonephritis in rats.<sup><xref ref-type="bibr" rid="bibr2-0961203313477225">2</xref>,<xref ref-type="bibr" rid="bibr3-0961203313477225">3</xref></sup> Central to the currently accepted theory underlying the initial development of MLN is acute in-situ subepithelial immune complex deposition and subsequent complement activation. However, the pathogenetic process responsible for chronic proteinuria is not addressed by this animal model and remains unknown in patients with membranous GN.</p>
<p>As is the case in the idiopathic form of MGN,<sup><xref ref-type="bibr" rid="bibr13-0961203313477225">13</xref>,<xref ref-type="bibr" rid="bibr14-0961203313477225">14</xref></sup> visceral epithelial cells in patients with SLE likely express a target antigen, which as yet remains unidentified.<sup><xref ref-type="bibr" rid="bibr15-0961203313477225">15</xref></sup> One might propose that the subepithelial immune deposits initiate podocyte injury in a T-helper-2 predominant fashion<sup><xref ref-type="bibr" rid="bibr16-0961203313477225">16</xref><xref ref-type="bibr" rid="bibr17-0961203313477225"/>–<xref ref-type="bibr" rid="bibr18-0961203313477225">18</xref></sup>), resulting in local complement activation and membrane attack complex (C5b-9) insertion into the visceral epithelial cell. In the passive Heymann model, membranous nephropathy is induced by the acute administration of a heterologous antibody. The C5b-9 attack complex has been shown to be responsible for the development of acute proteinuria.<sup><xref ref-type="bibr" rid="bibr19-0961203313477225">19</xref></sup> Studies performed in intact complement depleted rats with passive Heymann nephritis showed no evidence of proteinuria. Cobra venom factor was given to deplete C3 in rats injected with Fx1A, and proteinuria was 4 mg/day in the complement depleted rats versus 70 mg/day in the controls, yet the subepithelial deposit burden was similar in both groups. Animal models depleted of C6 with passive Heymann experimental membranous glomerulonephritis (MGN) did not develop proteinuria despite the ultrastructural demonstration of subepithelial immune complex deposition.<sup><xref ref-type="bibr" rid="bibr2-0961203313477225">2</xref></sup> Mounting evidence therefore points to sublytic C5b-9 podocyte injury causing acute glomerular capillary wall damage via multiple mechanisms which may not solely be a consequence of lethal pore formation.<sup><xref ref-type="bibr" rid="bibr20-0961203313477225">20</xref></sup> Finally, preliminary evidence in idiopathic MGN reveals a variety of podocyte antigens (aldose reductase, superoxide dismutase 2, and α-enolase) may be the direct target of the predominant antibody isotype, IgG<sub>4</sub>.<sup><xref ref-type="bibr" rid="bibr21-0961203313477225">21</xref></sup> The presence of these visceral epithelial cell antigens in the serum has been found to correlate with the degree of proteinuria in patients with idiopathic MGN.<sup><xref ref-type="bibr" rid="bibr21-0961203313477225">21</xref></sup></p>
<p>We observed no association between the amount of immune aggregates in the peripheral capillary loops or deposition of immune aggregates in the mesangium and amount of proteinuria, nor was there an association between the presence or density of peripheral capillary immune aggregate deposition with the extent of FPE. In addition, there was relatively little C3 demonstrated in the capillary walls.</p>
<p>Our data therefore supports the notion that chronic podocyte damage in nephrotic patients with MLN may not be limited to local complement mediated damage stimulated by immune aggregate deposition. In contrast to passive Heymann nephritis, an acute model dependent upon acute antibody mediated injury, active Heymann nephritis is a chronic model of MGN which results from the immunization of the animal to the inciting antigen. The chronic damage which is observed in active Heymann nephritis could therefore conceivably result from either humoral or cellular mechanisms of immune damage. In a study of active Heymann nephritis by Hess et al.<sup><xref ref-type="bibr" rid="bibr22-0961203313477225">22</xref></sup>, electron micrographs revealed evidence of visceral epithelial cell damage prior to the appearance of immune aggregate deposition in the subepithelial space of the glomerular basement membrane. One implication of this finding is the possibility that diffuse FPE could be independent of immune aggregate deposition.</p>
<p>An explanation for the degree of effacement in the nephrotic group of patients with MLN is a concomitant podocytopathy. Minimal change glomerulopathy associated with nephrotic syndrome has been described previously in patients with SLE, albeit without documented peripheral capillary wall immune deposits.<sup><xref ref-type="bibr" rid="bibr23-0961203313477225">23</xref><xref ref-type="bibr" rid="bibr24-0961203313477225"/><xref ref-type="bibr" rid="bibr25-0961203313477225"/><xref ref-type="bibr" rid="bibr26-0961203313477225"/><xref ref-type="bibr" rid="bibr27-0961203313477225"/><xref ref-type="bibr" rid="bibr28-0961203313477225"/><xref ref-type="bibr" rid="bibr29-0961203313477225"/>–<xref ref-type="bibr" rid="bibr30-0961203313477225">30</xref></sup> In 2005, Kraft et al.<sup><xref ref-type="bibr" rid="bibr31-0961203313477225">31</xref></sup> reported the development of nephrotic range proteinuria in eight SLE patients with no evidence of either mesangial or peripheral capillary immune aggregate deposition. Later, Han et al.<sup><xref ref-type="bibr" rid="bibr32-0961203313477225">32</xref></sup> studied a group of patients with nephrotic syndrome and SLE who had mesangial lupus nephritis, some of whom had rare subepithelial capillary wall deposits. The degree of proteinuria that we noted in MLN could therefore be a result of a primary podocytopathy, as seen in other patients with lupus nephritis.</p>
<p>Limitations of our study include its retrospective nature and small sample size given the rare occurrence of this disease and may be underpowered to detect a difference in all histologic features. In addition, the immunofluorescence data are semi-quantitative and the grading system is subjective. The use of electron microscopy for evaluating degree of deposits could be subject to sampling error. Lastly, it is possible that the podocyte abnormality that we report can be secondary to the amount of proteinuria and therefore unrelated to the pathogenetic events.</p>
<p>Our observations support the notion that podocytopathy may represent an independent pathogenetic process for the development of nephrotic range proteinuria. As nephrotic range proteinuria is one of the major indications for immunosuppressive therapy in MLN, this observation may promote the development of more specific targeted therapies in the future.</p>
</sec>
</body>
<back>
<sec id="sec10-0961203313477225"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec11-0961203313477225"><title>Conflict of interest</title>
<p>The authors have no competing financial interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203313477225"><label>1</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>H</given-names></name></person-group> <article-title>Lupus membranous nephropathy</article-title>. In: <person-group person-group-type="editor"><name><surname>Lewis</surname><given-names>E</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Korbet</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>T</given-names></name></person-group> (eds). <source>Lupus nephritis</source> , <edition>2nd ed</edition>. <publisher-loc>Oxford</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>, <year>2011</year>, pp. <fpage>169</fpage>–<lpage>197</lpage>.</citation></ref>
<ref id="bibr2-0961203313477225"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>PJ</given-names></name><name><surname>Ochi</surname><given-names>RF</given-names></name><name><surname>Schulze</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>RJ</given-names></name><name><surname>Campbell</surname><given-names>C</given-names></name><name><surname>Couser</surname><given-names>WG</given-names></name></person-group>. <article-title>Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats</article-title>. <source>Am J Pathol</source> <year>1989</year>; <volume>135</volume>: <fpage>185</fpage>–<lpage>194</lpage>.</citation></ref>
<ref id="bibr3-0961203313477225"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Couser</surname><given-names>WG</given-names></name><name><surname>Nangaku</surname><given-names>M</given-names></name></person-group>. <article-title>Cellular and molecular biology of membranous nephropathy</article-title>. <source>J Nephrol</source> <year>2006</year>; <volume>19</volume>: <fpage>699</fpage>–<lpage>705</lpage>.</citation></ref>
<ref id="bibr4-0961203313477225"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nangaku</surname><given-names>M</given-names></name><name><surname>Shankland</surname><given-names>SJ</given-names></name><name><surname>Couser</surname><given-names>WG</given-names></name></person-group>. <article-title>Cellular response to injury in membranous nephropathy</article-title>. <source>J Am Soc Nephrol</source> <year>2005</year>; <volume>16</volume>: <fpage>1195</fpage>–<lpage>1204</lpage>.</citation></ref>
<ref id="bibr5-0961203313477225"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulze</surname><given-names>M</given-names></name><name><surname>Donadio</surname><given-names>JV</given-names><suffix>Jr</suffix></name><name><surname>Pruchno</surname><given-names>CJ</given-names></name><etal/></person-group>. <article-title>Elevated urinary excretion of the C5b-9 complex in membranous nephropathy</article-title>. <source>Kidney Int</source> <year>1991</year>; <volume>40</volume>: <fpage>533</fpage>–<lpage>538</lpage>.</citation></ref>
<ref id="bibr6-0961203313477225"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>CE</given-names></name><name><surname>Wilmer</surname><given-names>WA</given-names></name><name><surname>Hernandez</surname><given-names>RA</given-names><suffix>Jr</suffix></name><etal/></person-group>. <article-title>Relapse or worsening of nephrotic syndrome in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated</article-title>. <source>Nephron Clin Pract</source> <year>2011</year>; <volume>119</volume>: <fpage>c145</fpage>–<lpage>c153</lpage>.</citation></ref>
<ref id="bibr7-0961203313477225"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van den Berg</surname><given-names>JG</given-names></name><name><surname>van den Bergh Weerman</surname><given-names>MA</given-names></name><name><surname>Assmann</surname><given-names>KJ</given-names></name><name><surname>Weening</surname><given-names>JJ</given-names></name><name><surname>Florquin</surname><given-names>S</given-names></name></person-group>. <article-title>Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies</article-title>. <source>Kidney Int</source> <year>2004</year>; <volume>66</volume>: <fpage>1901</fpage>–<lpage>1906</lpage>.</citation></ref>
<ref id="bibr8-0961203313477225"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gundersen</surname><given-names>HJ</given-names></name><name><surname>Seefeldt</surname><given-names>T</given-names></name><name><surname>Osterby</surname><given-names>R</given-names></name></person-group>. <article-title>Glomerular epithelial foot processes in normal man and rats. Distribution of true width and its intra- and inter-individual variation</article-title>. <source>Cell Tissue Res</source> <year>1980</year>; <volume>205</volume>: <fpage>147</fpage>–<lpage>155</lpage>.</citation></ref>
<ref id="bibr9-0961203313477225"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>LJ</given-names></name><name><surname>Ravirajan</surname><given-names>CT</given-names></name><name><surname>Rahman</surname><given-names>A</given-names></name><name><surname>Putterman</surname><given-names>C</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group>. <article-title>Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?</article-title> <source>Arthritis Rheum</source> <year>2004</year>; <volume>50</volume>: <fpage>866</fpage>–<lpage>870</lpage>.</citation></ref>
<ref id="bibr10-0961203313477225"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trivedi</surname><given-names>S</given-names></name><name><surname>Zeier</surname><given-names>M</given-names></name><name><surname>Reiser</surname><given-names>J</given-names></name></person-group>. <article-title>Role of podocytes in lupus nephritis</article-title>. <source>Nephrol Dial Transplant</source> <year>2009</year>; <volume>24</volume>: <fpage>3607</fpage>–<lpage>3612</lpage>.</citation></ref>
<ref id="bibr11-0961203313477225"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perysinaki</surname><given-names>GS</given-names></name><name><surname>Moysiadis</surname><given-names>DK</given-names></name><name><surname>Bertsias</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Podocyte main slit diaphragm proteins, nephrin and podocin, are affected at early stages of lupus nephritis and correlate with disease histology</article-title>. <source>Lupus</source> <year>2011</year>; <volume>20</volume>: <fpage>781</fpage>–<lpage>791</lpage>.</citation></ref>
<ref id="bibr12-0961203313477225"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moysiadis</surname><given-names>DK</given-names></name><name><surname>Perysinaki</surname><given-names>GS</given-names></name><name><surname>Bertsias</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Early treatment with glucocorticoids or cyclophosphamide retains the slit diaphragm proteins nephrin and podocin in experimental lupus nephritis</article-title>. <source>Lupus</source> <year>2012</year>; <volume>21</volume>: <fpage>1196</fpage>–<lpage>1207</lpage>.</citation></ref>
<ref id="bibr13-0961203313477225"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Couser</surname><given-names>WG</given-names></name><name><surname>Stilmant</surname><given-names>MM</given-names></name><name><surname>Darby</surname><given-names>C</given-names></name></person-group>. <article-title>Autologous immune complex nephropathy. I. Sequential study of immune complex deposition, ultrastructural changes, proteinuria, and alterations in glomerular sialoprotein</article-title>. <source>Lab Invest</source> <year>1976</year>; <volume>34</volume>: <fpage>23</fpage>–<lpage>30</lpage>.</citation></ref>
<ref id="bibr14-0961203313477225"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heymann</surname><given-names>W</given-names></name><name><surname>Hackel</surname><given-names>DB</given-names></name><name><surname>Harwood</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>SG</given-names></name><name><surname>Hunter</surname><given-names>JL</given-names></name></person-group>. <article-title>Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions</article-title>. <source>Proc Soc Exp Biol Med</source> <year>1959</year>; <volume>100</volume>: <fpage>660</fpage>–<lpage>664</lpage>.</citation></ref>
<ref id="bibr15-0961203313477225"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murtas</surname><given-names>C</given-names></name><name><surname>Ravani</surname><given-names>P</given-names></name><name><surname>Ghiggeri</surname><given-names>GM</given-names></name></person-group>. <article-title>New insights into membranous glomerulonephritis: From bench to bedside</article-title>. <source>Nephrol Dial Transplant</source> <year>2011</year>; <volume>26</volume>: <fpage>2428</fpage>–<lpage>2430</lpage>.</citation></ref>
<ref id="bibr16-0961203313477225"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirayama</surname><given-names>K</given-names></name><name><surname>Ebihara</surname><given-names>I</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Predominance of type-2 immune response in idiopathic membranous nephropathy. Cytoplasmic cytokine analysis</article-title>. <source>Nephron</source> <year>2002</year>; <volume>91</volume>: <fpage>255</fpage>–<lpage>261</lpage>.</citation></ref>
<ref id="bibr17-0961203313477225"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>J</given-names></name><name><surname>Sakai</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Evaluation of T helper-1/-2 balance on the basis of IgG subclasses and serum cytokines in children with glomerulonephritis</article-title>. <source>Am J Kidney Dis</source> <year>2004</year>; <volume>44</volume>: <fpage>42</fpage>–<lpage>49</lpage>.</citation></ref>
<ref id="bibr18-0961203313477225"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Masutani</surname><given-names>K</given-names></name><name><surname>Taniguchi</surname><given-names>M</given-names></name><name><surname>Nakashima</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Up-regulated interleukin-4 production by peripheral T-helper cells in idiopathic membranous nephropathy</article-title>. <source>Nephrol Dial Transplant</source> <year>2004</year>; <volume>19</volume>: <fpage>580</fpage>–<lpage>586</lpage>.</citation></ref>
<ref id="bibr19-0961203313477225"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salant</surname><given-names>DJ</given-names></name><name><surname>Belok</surname><given-names>S</given-names></name><name><surname>Madaio</surname><given-names>MP</given-names></name><name><surname>Couser</surname><given-names>WG</given-names></name></person-group>. <article-title>A new role for complement in experimental membranous nephropathy in rats</article-title>. <source>J Clin Invest</source> <year>1980</year>; <volume>66</volume>: <fpage>1339</fpage>–<lpage>1350</lpage>.</citation></ref>
<ref id="bibr20-0961203313477225"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fosbrink</surname><given-names>M</given-names></name><name><surname>Niculescu</surname><given-names>F</given-names></name><name><surname>Rus</surname><given-names>H</given-names></name></person-group>. <article-title>The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription</article-title>. <source>Immunol Res</source> <year>2005</year>; <volume>31</volume>: <fpage>37</fpage>–<lpage>46</lpage>.</citation></ref>
<ref id="bibr21-0961203313477225"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murtas</surname><given-names>C</given-names></name><name><surname>Bruschi</surname><given-names>M</given-names></name><name><surname>Candiano</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy</article-title>. <source>Clin J Am Soc Nephrol</source> <year>2012</year>; <volume>7</volume>: <fpage>1394</fpage>–<lpage>1400</lpage>.</citation></ref>
<ref id="bibr22-0961203313477225"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>EV</given-names></name><name><surname>Ashworth</surname><given-names>CT</given-names></name><name><surname>Ziff</surname><given-names>M</given-names></name></person-group>. <article-title>Transfer of an autoimmune nephrosis in the rat by means of lymph node cells</article-title>. <source>J Exp Med</source> <year>1962</year>; <volume>115</volume>: <fpage>421</fpage>–<lpage>438</lpage>.</citation></ref>
<ref id="bibr23-0961203313477225"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hertig</surname><given-names>A</given-names></name><name><surname>Droz</surname><given-names>D</given-names></name><name><surname>Lesavre</surname><given-names>P</given-names></name><name><surname>Grunfeld</surname><given-names>JP</given-names></name><name><surname>Rieu</surname><given-names>P</given-names></name></person-group>. <article-title>SLE and idiopathic nephrotic syndrome: Coincidence or not?</article-title> <source>Am J Kidney Dis</source> <year>2002</year>; <volume>40</volume>: <fpage>1179</fpage>–<lpage>1184</lpage>.</citation></ref>
<ref id="bibr24-0961203313477225"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horita</surname><given-names>Y</given-names></name><name><surname>Nazneen</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>[A case of systemic lupus erythematosus associated with minimal change nephrotic syndrome.]</article-title>. <source>Nihon Jinzo Gakkai Shi</source> <year>1997</year>; <volume>39</volume>: <fpage>759</fpage>–<lpage>764</lpage>.</citation></ref>
<ref id="bibr25-0961203313477225"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hunley</surname><given-names>TE</given-names></name><name><surname>Yared</surname><given-names>A</given-names></name><name><surname>Fogo</surname><given-names>A</given-names></name><name><surname>MacDonell</surname><given-names>RC</given-names><suffix>Jr</suffix></name></person-group>. <article-title>Nephrotic syndrome in an adolescent: The cry of the wolf</article-title>. <source>Am J Kidney Dis</source> <year>1998</year>; <volume>31</volume>: <fpage>155</fpage>–<lpage>160</lpage>.</citation></ref>
<ref id="bibr26-0961203313477225"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Makino</surname><given-names>H</given-names></name><name><surname>Haramoto</surname><given-names>T</given-names></name><name><surname>Shikata</surname><given-names>K</given-names></name><name><surname>Ogura</surname><given-names>T</given-names></name><name><surname>Ota</surname><given-names>Z</given-names></name></person-group>. <article-title>Minimal-change nephrotic syndrome associated with systemic lupus erythematosus</article-title>. <source>Am J Nephrol</source> <year>1995</year>; <volume>15</volume>: <fpage>439</fpage>–<lpage>441</lpage>.</citation></ref>
<ref id="bibr27-0961203313477225"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsumura</surname><given-names>N</given-names></name><name><surname>Dohi</surname><given-names>K</given-names></name><name><surname>Shiiki</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>[Three cases presenting with systemic lupus erythematosus and minimal change nephrotic syndrome.]</article-title>. <source>Nihon Jinzo Gakkai Shi</source> <year>1989</year>; <volume>31</volume>: <fpage>991</fpage>–<lpage>999</lpage>.</citation></ref>
<ref id="bibr28-0961203313477225"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nishihara</surname><given-names>G</given-names></name><name><surname>Nakamoto</surname><given-names>M</given-names></name><name><surname>Yasunaga</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Systemic lupus erythematosus in a patient with remitting minimal change nephrotic syndrome</article-title>. <source>Clin Nephrol</source> <year>1997</year>; <volume>48</volume>: <fpage>327</fpage>–<lpage>330</lpage>.</citation></ref>
<ref id="bibr29-0961203313477225"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okai</surname><given-names>T</given-names></name><name><surname>Soejima</surname><given-names>A</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>[A case report of lupus nephritis associated with minimal change nephrotic syndrome – comparison of various histological types of 67 cases with lupus nephritis.]</article-title>. <source>Nihon Jinzo Gakkai Shi</source> <year>1992</year>; <volume>34</volume>: <fpage>835</fpage>–<lpage>840</lpage>.</citation></ref>
<ref id="bibr30-0961203313477225"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perakis</surname><given-names>C</given-names></name><name><surname>Arvanitis</surname><given-names>A</given-names></name><name><surname>Sotsiou</surname><given-names>F</given-names></name><name><surname>Emmanouel</surname><given-names>DS</given-names></name></person-group>. <article-title>Nephrotic syndrome caused by minimal-change disease in a patient with focal proliferative SLE nephritis (WHO III) in remission</article-title>. <source>Nephrol Dial Transplant</source> <year>1998</year>; <volume>13</volume>: <fpage>467</fpage>–<lpage>470</lpage>.</citation></ref>
<ref id="bibr31-0961203313477225"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kraft</surname><given-names>SW</given-names></name><name><surname>Schwartz</surname><given-names>MM</given-names></name><name><surname>Korbet</surname><given-names>SM</given-names></name><name><surname>Lewis</surname><given-names>EJ</given-names></name></person-group>. <article-title>Glomerular podocytopathy in patients with systemic lupus erythematosus</article-title>. <source>J Am Soc Nephrol</source> <year>2005</year>; <volume>16</volume>: <fpage>175</fpage>–<lpage>179</lpage>.</citation></ref>
<ref id="bibr32-0961203313477225"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>TS</given-names></name><name><surname>Schwartz</surname><given-names>MM</given-names></name><name><surname>Lewis</surname><given-names>EJ</given-names></name></person-group>. <article-title>Association of glomerular podocytopathy and nephrotic proteinuria in mesangial lupus nephritis</article-title>. <source>Lupus</source> <year>2006</year>; <volume>15</volume>: <fpage>71</fpage>–<lpage>75</lpage>.</citation></ref>
</ref-list>
</back>
</article>